BRD4 and neuroblastoma: CDK7 phosphorylates serine 5 of Pol2 at the promoter to promote initiation [32], and it has been shown that CDK7 inhibitors have a synergistic effect when combined with BRD4 inhibitors in neuroblastoma [33], so a local increase in CDK7 could also be implicated.